Retrogenix

Retrogenix, a biotechnology startup, is leading the way in medical research and drug discovery with its unique approach to identifying specific cell surface and secreted protein interactions in human cells. The company collaborates with nineteen of the top twenty global pharmaceutical companies, as well as numerous drug discovery firms, academic institutions, and non-profit organizations worldwide. Their groundbreaking findings have been recognized in prestigious journals such as Nature and Cancer Cell, and their team members are frequent presenters at international conferences.

In 2015, Retrogenix was honored with its first Queen’s Award for Enterprise, followed by a second in 2017 for outstanding achievements in international trade, showcasing the company's innovative work in developing and commercializing cell microarray technology.

Retrogenix boasts one of the world’s largest collections of plasma membrane and secreted protein clones, surpassing 5,500 full-length expression clones, with many proteins represented by multiple variants. This exceptional collection, combined with their unique cell microarray technology, positions Retrogenix as a key player in accelerating global medical innovation and empowering groundbreaking drug discoveries.